Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mariame Layba Camara1, Moïse Kagbadouno1, Ansoumane Kourouma1

  • 1Programme National de Lutte contre les MTN à Prise en Charge des Cas, Conakry, Guinée.

Sante Publique (Vandoeuvre-Les-Nancy, France)
|June 23, 2025
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elimination of gambiense human African trypanosomiasis as a public health problem in Republic of Guinea: Paving the way for zero transmission.

PLoS neglected tropical diseases·2026
Same author

[Descriptive analytical study of patient survival with vertebral metastases in a rheumatological setting in Togo].

The Pan African medical journal·2026
Same author

Xeno-monitoring the impact of Vector Control on trypanosome transmission in the Forecariah sleeping sickness focus (Guinea).

PLoS neglected tropical diseases·2026
Same author

Characteristics and dynamics of malaria vectors around the Soum dam in Nanoro Health District, Burkina Faso.

PloS one·2026
Same author

Challenges in malaria diagnosis and treatment in Kinshasa Province, Democratic Republic of the Congo.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Human Leukocyte Antigen-G is enriched in presence of trypanosome in the dermis of individuals exposed to gambiense Human African Trypanosomiasis in Guinea and Côte d'Ivoire.

PLoS neglected tropical diseases·2026

This study assessed the feasibility of a new human African trypanosomiasis (HAT) drug in Guinea. Findings show high acceptance for the oral treatment, indicating potential for successful implementation.

Area of Science:

  • Neglected tropical diseases
  • Parasitology
  • Global health

Context:

  • Human African trypanosomiasis (HAT), also known as sleeping sickness, is a vector-borne parasitic disease endemic to sub-Saharan Africa.
  • The coastal region of Guinea, specifically the foci of Boffa, Dubréka, and Forécariah, represents a key area for HAT control efforts.
  • The introduction of new, potentially more effective treatments is crucial for improving patient outcomes and disease elimination strategies.

Purpose:

  • To evaluate the feasibility of implementing a new oral drug for human African trypanosomiasis (HAT) in three endemic regions of Guinea.
  • To assess community knowledge, perceptions, and acceptance of the new HAT treatment.
  • To identify potential barriers and facilitators for the successful rollout of the new therapeutic option.

Summary:

Keywords:
Guinea.communityfeasibilitygHAToral treatment

Related Experiment Videos

  • A cross-sectional study in Guinea revealed that while knowledge of HAT transmission was moderate (27.5%), awareness of a new treatment was higher (49.6%).
  • Respondents recognized key advantages of the new treatment, including non-invasiveness (no lumbar puncture required) and being free of charge.
  • Overwhelming acceptance was reported for the oral HAT treatment, with high willingness to self-administer at home and reduced perceived stigma.

Impact:

  • The study highlights a strong potential for the successful adoption of the new oral HAT treatment in Guinea.
  • Findings suggest that community engagement and education on HAT transmission and treatment benefits are vital for successful implementation.
  • The high acceptance rate indicates that the new drug could significantly improve treatment adherence and reduce the burden of HAT in endemic areas.